Literature DB >> 16359538

Solitary fibrous tumour and haemangiopericytoma: evolution of a concept.

C Gengler1, L Guillou.   

Abstract

Haemangiopericytoma (HPC) was described in 1942 by Stout and Murray as a distinctive soft tissue neoplasm, presumably of pericytic origin, exhibiting a characteristic well-developed "staghorn" branching vascular pattern. Over the years, it appeared that this growth pattern was a non-specific one, shared by numerous, unrelated benign and malignant lesions, and that HPC was better considered as a diagnosis of exclusion. Three categories of lesion may now be individualized within the heterogeneous group of HPC-like neoplasms. The first category corresponds to those non-HPC neoplasms that occasionally display HPC-like features (e.g. synovial sarcoma). Lesions belonging to the second category show clear evidence of myoid/pericytic differentiation and correspond to true HPCs. They generally show a benign clinical course, and include glomangiopericytoma/myopericytoma, infantile myofibromatosis (previously called infantile HPC), and a subset of sinonasal HPCs. The third category is the solitary fibrous tumour (SFT) lesional group, which includes fibrous-to-cellular SFTs, and related lesions such as giant cell angiofibromas and lipomatous HPCs. In practice, any HPC-like lesion can be allocated to one of these categories, leaving the ill-defined "haemangiopericytoma" category empty.

Entities:  

Mesh:

Year:  2006        PMID: 16359538     DOI: 10.1111/j.1365-2559.2005.02290.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  145 in total

1.  Solitary fibrous tumor with giant multinucleated cells in the retroperitoneum - a case report.

Authors:  Amel Trabelsi; Faten Hammedi; Soumaya Rammeh; Soumaya Ben Abdelkrim; Lilia Ben Yacoub-Abid; Nadia Beïzig; Badreddine Sriha
Journal:  N Am J Med Sci       Date:  2009-10

2.  Fat-forming variant of solitary fibrous tumour of the pleura: CT findings.

Authors:  C Y Park; J Y Rho; S M Yoo; H K Jung
Journal:  Br J Radiol       Date:  2011-11       Impact factor: 3.039

Review 3.  Parotid gland solitary fibrous tumor: a case report and clinicopathologic review of 22 cases from the literature.

Authors:  Justin L Bauer; Andrew Z Miklos; Lester D R Thompson
Journal:  Head Neck Pathol       Date:  2011-10-16

Review 4.  Solitary fibrous tumor of small bowel mesentery with postoperative bowel obstruction: a case report and review of literature.

Authors:  Guo-Jing Zhang; Ruo-Tong Li; Yang Zhou; Fei Huang; Zhi-Cheng Zhao; Wei-Dong Li; Wei-Hua Fu
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

5.  Orbit Solitary Fibrous Tumor: A Proposed Risk Prediction Model Based on a Case Series and Comprehensive Literature Review.

Authors:  Lester D R Thompson; Sofia S Liou; Kenneth A Feldman
Journal:  Head Neck Pathol       Date:  2020-06-11

Review 6.  [Modern morphological diagnosis and current classification of soft tissue sarcomas].

Authors:  D Katenkamp; K Katenkamp
Journal:  Chirurg       Date:  2009-03       Impact factor: 0.955

7.  Solitary fibrous tumors in abdomen and pelvis: imaging characteristics and radiologic-pathologic correlation.

Authors:  Xue-Ming Li; Jing Reng; Peng Zhou; Ying Cao; Zhu-Zhong Cheng; Yan Xiao; Guo-Hui Xu
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

Review 8.  Ocular adnexal (orbital) solitary fibrous tumor: nuclear STAT6 expression and literature review.

Authors:  Aleksandra Petrovic; Aurélie Obéric; Alexandre Moulin; Mehrad Hamedani
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-03-13       Impact factor: 3.117

Review 9.  Treatment of orbital solitary fibrous tumour with gamma knife radiosurgery and systematic review of literature.

Authors:  Athreya Tata; Or Cohen-Inbar; Jason P Sheehan
Journal:  BMJ Case Rep       Date:  2016-10-07

10.  [Solitary fibrous tumor and haemangiopericytoma: what is new?].

Authors:  T Knösel; B Schulz; K Katenkamp; D Katenkamp; I Petersen
Journal:  Pathologe       Date:  2010-03       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.